NUTRA PHARMA Business Summary

Nutra Pharma Corp (NPHC) is a development-stage biopharmaceutical company that generates revenue primarily through the production and sale of over-the-counter (OTC) homeopathic pain relief products and contract manufacturing services. Its core product portfolio includes Nyloxin and Nyloxin Extra Strength for chronic pain, alongside specialized brands such as Pet Pain-Away for companion animals, Equine Pain-Away for horses, and Luxury Feet for foot pain. The company operates as a single reportable segment, leveraging its in-house manufacturing capabilities in Florida to provide formulation and production services for third-party partners like Avini Health. Within the competitive landscape, Nutra Pharma contends with biotechnology and specialty pharmaceutical firms such as Amgen, Neurocrine Biosciences, and Vertex Pharmaceuticals. As of mid-2026, the company remains a micro-cap entity facing significant liquidity challenges, characterized by a substantial stockholders' deficit and a persistent going-concern warning in its financial filings. The leadership team is currently headed by Dr. Michael Flax, who serves as Chairman, President, Chief Executive Officer, and Chief Financial Officer, having resumed these roles in March 2024 following a settlement with the SEC. Dr. Flax, a Doctor of Dental Surgery (DDS) and long-term investor, oversees the company's strategic direction alongside Chief Scientific Officer Dale Vanderputten, PhD, who leads the clinical development of proprietary drug candidates RPI-78M and RPI-MN for neurological and viral diseases. The executive team also includes Joe Lucas as Vice President of Operations, with former CEO Rik J. Deitsch serving as Operations Manager. The Board of Directors is composed of independent members Stewart Lonky, M.D., and Garry Pottruck, who provide clinical and governance oversight. Notable recent activity includes a 2026 settlement with investor Marc Weller, reflecting the company's ongoing efforts to restructure its debt-heavy balance sheet.